{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T01:17:52Z","timestamp":1778375872405,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"e3","funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organization for Health Research and Development","doi-asserted-by":"crossref","award":["836031012"],"award-info":[{"award-number":["836031012"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2022,6,21]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Morphine is used as palliative treatment of chronic breathlessness in patients with chronic obstructive pulmonary disease (COPD). Part of the patients does not experience a clinically meaningful improvement of breathlessness and it is unclear which characteristics are related to a clinically meaningful improvement of breathlessness after morphine. Therefore, this study assessed whether sensory breathlessness description, demographic and clinical characteristics are related with this improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cross-sectional secondary analysis of the intervention arm of a randomised controlled trial. 45 patients with COPD and moderate-to-very severe chronic breathlessness despite optimal treatment received 20\u201330 mg oral sustained-release morphine daily for 4 weeks. Using binary logistic regression, the relationship between a clinically meaningful improvement in breathlessness (\u22651 point on 0\u201310 numeric rating scale) and the baseline variables sensory breathlessness descriptors, age, breathlessness and body mass index (BMI) was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-one participants (42%) showed a clinically meaningful improvement. Baseline breathlessness (OR 1.51, 95% CI 1.04 to 2.21, p=0.03) and BMI (OR 1.13, 95% 1.02\u20131.28, p=0.02) were significant associated to a clinically meaningful improvement of breathlessness, while age and sensory breathlessness descriptors were not.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Worse baseline breathlessness and higher BMI are associated to a clinically meaningful improvement of breathlessness in patients using 20\u201330 mg oral sustained-release morphine. Opioid treatment should be considered in patients with COPD with severe breathlessness, taking into account the patient\u2019s BMI.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2022-003693","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T17:25:19Z","timestamp":1658165119000},"page":"e829-e832","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Morphine for chronic breathlessness in COPD: improvement predictors-cross-sectional study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-1256","authenticated-orcid":false,"given":"Cornelia A","family":"Verberkt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke H J","family":"van den Beuken-Everdingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos M G A","family":"Schols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiel F M","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy J A","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"2024121022580598000_13.e3.e829.1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2010.0479"},{"key":"2024121022580598000_13.e3.e829.2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912748"},{"key":"2024121022580598000_13.e3.e829.3","first-page":"CD011008","article-title":"Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness","volume":"3","author":"Barnes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024121022580598000_13.e3.e829.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.11.021"},{"key":"2024121022580598000_13.e3.e829.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139812"},{"key":"2024121022580598000_13.e3.e829.6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cct.2016.01.007","article-title":"A randomized controlled trial on the benefits and respiratory adverse effects of morphine for refractory dyspnea in patients with COPD: protocol of the MORDYC study","volume":"47","author":"Verberkt","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"2024121022580598000_13.e3.e829.7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamainternmed.2020.3134","article-title":"Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial","volume":"180","author":"Verberkt","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2024121022580598000_13.e3.e829.8","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report, 2020."},{"key":"2024121022580598000_13.e3.e829.9","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.7.581"},{"key":"2024121022580598000_13.e3.e829.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.01.011"},{"key":"2024121022580598000_13.e3.e829.11","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.156372"},{"key":"2024121022580598000_13.e3.e829.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2011.06.009"},{"key":"2024121022580598000_13.e3.e829.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00038914"},{"key":"2024121022580598000_13.e3.e829.14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.phrs.2016.08.031","article-title":"The effect of morbid obesity on morphine glucuronidation","volume":"118","author":"Lloret-Linares","year":"2017","journal-title":"Pharmacol Res"},{"key":"2024121022580598000_13.e3.e829.15","unstructured":"Integraal Kankercentrum Nederland . Palliatieve zorg bij COPD. 2.0 ed 2021."}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2022-003693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:16:50Z","timestamp":1733901410000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2022-003693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":15,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2022-003693"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2022-003693","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}